Emily Harris1, Bernard Ng2. 1. University of Washington School of Medicine, Seattle, Washington, USA. 2. Department of Rheumatology, University of Washington School of Medicine, Seattle, Washington, USA.
Abstract
OBJECTIVE: Our study aims to determine whether the use of subcutaneous methotrexate (SC MTX) is associated with prolonged MTX use and lower incidence of hepatotoxicity in rheumatoid arthritis (RA) patients on MTX monotherapy and multiple drug therapy. METHODS: We conducted a retrospective cohort study using national databases of a large hospital system. Subjects had been diagnosed with RA and treated with MTX between September 30, 1999, and October 1, 2009. Outcomes of interest were the amount of time on MTX monotherapy or multiple disease-modifying anti-rheumatic drug (DMARD) therapy before addition of additional DMARDs or biologic agents, respectively. We conducted Cox regressions and Kaplan-Meier curves for association between SC MTX use and length of time before therapeutic change. We conducted chi-square tests for association between SC MTX use and elevated liver function tests (LFT). RESULTS: MTX monotherapy: SC MTX was associated with a significantly lower likelihood of therapeutic change (HR 0.64, 95% CI 0.52-0.78). Multiple DMARD therapy: SC MTX was not associated with a lower risk of adding a biologic (HR 1.13, 95% CI 0.97-1.31). Liver enzymes: There was no significant association between use of SC MTX and decreased frequency of abnormal LFTs [p=0.09 for alanine aminotransferase (ALT), p=0.924 for aspartate aminotransferase (AST)]. CONCLUSION: Use of SC MTX is associated with longer duration of MTX monotherapy before addition of other DMARDs/biologic agents in RA patients. Use of SC MTX is not associated with significantly longer duration of multiple DMARD therapy before addition of biologic agents. Use of oral MTX is not significantly associated with increased frequency of elevated LFTs.
OBJECTIVE: Our study aims to determine whether the use of subcutaneous methotrexate (SCMTX) is associated with prolonged MTX use and lower incidence of hepatotoxicity in rheumatoid arthritis (RA) patients on MTX monotherapy and multiple drug therapy. METHODS: We conducted a retrospective cohort study using national databases of a large hospital system. Subjects had been diagnosed with RA and treated with MTX between September 30, 1999, and October 1, 2009. Outcomes of interest were the amount of time on MTX monotherapy or multiple disease-modifying anti-rheumatic drug (DMARD) therapy before addition of additional DMARDs or biologic agents, respectively. We conducted Cox regressions and Kaplan-Meier curves for association between SCMTX use and length of time before therapeutic change. We conducted chi-square tests for association between SCMTX use and elevated liver function tests (LFT). RESULTS:MTX monotherapy: SCMTX was associated with a significantly lower likelihood of therapeutic change (HR 0.64, 95% CI 0.52-0.78). Multiple DMARD therapy: SCMTX was not associated with a lower risk of adding a biologic (HR 1.13, 95% CI 0.97-1.31). Liver enzymes: There was no significant association between use of SCMTX and decreased frequency of abnormal LFTs [p=0.09 for alanine aminotransferase (ALT), p=0.924 for aspartate aminotransferase (AST)]. CONCLUSION: Use of SCMTX is associated with longer duration of MTX monotherapy before addition of other DMARDs/biologic agents in RApatients. Use of SCMTX is not associated with significantly longer duration of multiple DMARD therapy before addition of biologic agents. Use of oral MTX is not significantly associated with increased frequency of elevated LFTs.
Authors: Stephan Pavy; Arnaud Constantin; Thao Pham; Laure Gossec; Jean-Francis Maillefert; Alain Cantagrel; Bernard Combe; René-Marc Flipo; Philippe Goupille; Xavier Le Loët; Xavier Mariette; Xavier Puéchal; Thierry Schaeverbeke; Jean Sibilia; Jacques Tebib; Daniel Wendling; Maxime Dougados Journal: Joint Bone Spine Date: 2006-03-23 Impact factor: 4.929
Authors: Licia Maria Henrique da Mota; Boris Afonso Cruz; Claiton Viegas Brenol; Ivanio Alves Pereira; Lucila Stange Rezende-Fronza; Manoel Barros Bertolo; Max Victor Carioca de Freitas; Nilzio Antonio da Silva; Paulo Louzada-Júnior; Rina Dalva Neubarth Giorgi; Rodrigo Aires Corrêa Lima; Geraldo da Rocha Castelar Pinheiro Journal: Rev Bras Reumatol Date: 2012 Mar-Apr
Authors: Jeffrey D Greenberg; Tanya M Spruill; Ying Shan; George Reed; Joel M Kremer; Jeffrey Potter; Yusuf Yazici; Gbenga Ogedegbe; Leslie R Harrold Journal: Am J Med Date: 2013-12 Impact factor: 4.965
Authors: Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon Journal: Arthritis Rheumatol Date: 2015-11-06 Impact factor: 10.995